Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Silence Therapeutics pleased with pipeline progress of Quark Pharma

Quark has dosed the first patient in a phase III trial of its QPI-1002 drug which uses Silence’s chemical modification technology
scientist with a microscope
If the drug is a success, Silence stands to receive royalties from Quark

An Israeli pharma group which has licensed Silence Therapeutics PLC's (LON:SLN) chemical modification technology has dosed the first patient in a phase III trial of its acute kidney injury treatment.

Quark Pharmaceuticals also announced it has reached an agreement with the US Food and Drug Administration on the overall study design with a new primary endpoint.

Silence is eligible to receive either approximately 1.5%-4% royalties from Quark on the QPI-1002 drug plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

“We are pleased to see the pipeline progress made by Quark Pharmaceuticals,” said Silence executive chair Annalisa Jenkins.

“Based upon positive data observed in their phase II programme, Quark have successfully transitioned to a major pivotal phase III programme for patients at high risk post cardiac surgery requiring prevention of Acute Kidney Injury (AKI).

“This significant global siRNA programme includes proprietary chemical modification technology developed by Silence Therapeutics.”

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use